New drug combo takes on tough lung cancer

NCT ID NCT07550842

Not yet recruiting Disease control Sponsor: Shanghai Best-Link Bioscience, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called BL0020 combined with the immunotherapy Toripalimab in 33 people whose extensive-stage small cell lung cancer has returned after initial treatment. The main goal is to check safety and find the right dose, while also seeing if the combination can shrink tumors. It is an open-label study, meaning everyone gets the active treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL0020 (a drug) combined with Toripalimab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with recurrent extensive-stage small cell lung cancer.
What could go wrong: This is a very early Phase 1 trial with only 33 participants, so it is primarily testing safety. The combination may not shrink tumors or improve survival, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL CARCINOMA OF LUNG

Contacts and locations

Locations

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital

Zhengzhou, Henan, 450008, China
Shanghai Chest Hospital

Shanghai, 200030, China
Shanghai Pulmonary Hospital

Shanghai, 200433, China
Taizhou Hospital of Zhejiang Province

Taizhou, Zhejiang, 317000, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110001, China
The First People's Hospital of Changzhou

Changzhou, Jiangsu, 213003, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.